Sodium-glucose cotransporter 2 (SGLT2) inhibitors was not previously recommended for use in patients with type 2 diabetes and renal impairment because their blood glucose lowering effect was insufficient [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.